Scioderm, Inc., an Amicus Therapeutics Company
Research - Durham, North Carolina, United States
Scioderm, Inc., an Amicus Therapeutics Company Employees
Scioderm, Inc., an Amicus Therapeutics Company Details
Scioderm, Inc. was acquired by Amicus Therapeutics, Inc. in September of 2015. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare genetic diseases.Amicus, together with Scioderm, was developing an investigational topical treatment (SD-101) for people with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder. In September of 2017, results of a Phase 3 clinical study to assess the efficacy and safety of SD-101, showed that it did not show a statistically significant difference from placebo. Subsequently, Amicus discontinued the program, but shared the clinical data and additional information related to the EB program with key stakeholders including other companies with investigational treatments for EB as well as the broader EB community.
Scioderm, Inc., an Amicus Therapeutics Company Technologies
Email Providers
Mimecast
Customer Relationship Management
Salesforce
Hosting
Liquidweb
Email Delivery
Amazon SES